Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $4.06 per share which missed the analyst consensus estimate of $4.32 by 6.02 percent. This is a 14.71 percent decrease over earnings of $4.76 per share from the same period last year. The company reported quarterly sales of $2.77 billion which missed the analyst consensus estimate of $2.85 billion by 2.90 percent. This is a 2.97 percent increase over sales of $2.69 billion the same period last year.